9 Meters leaps on positive Phase II results for short bowel syndrome

27 September 2022
biotech_lab_research_2022_big-1

North Carolina, USA-based 9 Meters Biopharma (Nasdaq: NMTR) saw its shares rise nearly 22% to $0.25, after it announced positive final results from the Phase II study of vurolenatide and the outcome from its End-of-Phase II meeting with the US Food and Drug Administration (FDA).

Vurolenatide, previously known as NB 1001, is a proprietary long-acting glucagon like peptide1 (GLP-1) receptor agonist in development for adults with short bowel syndrome (SBS). Based on the outcome from the meeting and the Phase II data, 9 Meters intends to finalize the Phase III protocol in collaboration with the FDA during the fourth quarter. Clinical plans and activities are currently underway to facilitate initiation of the study upon protocol finalization.

This seems to be an encouraging result for the biotech, which earlier this year suffered a setback with what was its lead candidate CedLara (lazarotide), which failed to demonstrate a significant impact on coeliac disease symptoms in a Phase III trial, as a result of which 9 Meters has switched its attention to vurolenatide.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology